Cipmolnu contains Molnupiravir, an oral antiviral medication used to treat mild to moderate COVID-19 in adults who are at risk of developing severe disease. It helps reduce viral replication, lowering the risk of hospitalization or death.

Mechanism of action:
Molnupiravir works by introducing errors into the viral RNA during replication. This causes the virus to produce defective copies of itself, ultimately preventing it from multiplying in the body and helping the immune system clear the infection.

Uses:

• Treatment of mild to moderate COVID-19 in adults at high risk of severe disease

• Helps reduce hospitalization and death related to COVID-19

• Usually prescribed within 5 days of symptom onset

Adverse effects:
Common side effects include diarrhea, nausea, dizziness, and headache. Rare but serious effects may include allergic reactions or liver problems. Safety in pregnant and breastfeeding women is not well established, so caution is advised.